| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
|
Blood
|
2002
|
12.46
|
|
2
|
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
|
J Clin Oncol
|
2012
|
4.34
|
|
3
|
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2011
|
3.01
|
|
4
|
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
|
Blood
|
2011
|
2.50
|
|
5
|
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
|
J Clin Oncol
|
2004
|
2.49
|
|
6
|
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2005
|
2.41
|
|
7
|
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2009
|
2.25
|
|
8
|
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
|
Blood
|
2003
|
2.23
|
|
9
|
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2005
|
2.16
|
|
10
|
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Blood
|
2010
|
2.03
|
|
11
|
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
|
J Clin Oncol
|
2012
|
1.98
|
|
12
|
Acute myeloid leukemia.
|
J Natl Compr Canc Netw
|
2012
|
1.96
|
|
13
|
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
|
J Clin Oncol
|
2012
|
1.79
|
|
14
|
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
|
Blood
|
2012
|
1.77
|
|
15
|
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
|
J Clin Oncol
|
2007
|
1.76
|
|
16
|
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
|
J Clin Oncol
|
2010
|
1.74
|
|
17
|
Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.
|
J Clin Oncol
|
2006
|
1.52
|
|
18
|
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2011
|
1.51
|
|
19
|
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Blood
|
2010
|
1.49
|
|
20
|
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
|
J Clin Oncol
|
2008
|
1.45
|
|
21
|
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2012
|
1.40
|
|
22
|
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.
|
Haematologica
|
2013
|
1.36
|
|
23
|
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
|
J Clin Oncol
|
2004
|
1.32
|
|
24
|
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Blood
|
2010
|
1.30
|
|
25
|
Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification.
|
Blood
|
2006
|
1.29
|
|
26
|
Acute myeloid leukemia, version 2.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.26
|
|
27
|
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
|
J Clin Oncol
|
2009
|
1.24
|
|
28
|
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.
|
Blood
|
2004
|
1.20
|
|
29
|
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
|
J Clin Oncol
|
2004
|
1.19
|
|
30
|
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.
|
Blood
|
2011
|
1.18
|
|
31
|
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
|
Am J Hematol
|
2007
|
1.14
|
|
32
|
Acute myeloid leukemia.
|
J Natl Compr Canc Netw
|
2011
|
1.09
|
|
33
|
Chronic Myelogenous Leukemia, Version 1.2014.
|
J Natl Compr Canc Netw
|
2013
|
1.07
|
|
34
|
Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases.
|
Am J Surg Pathol
|
2003
|
1.07
|
|
35
|
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
|
J Clin Oncol
|
2005
|
1.07
|
|
36
|
Chronic myelogenous leukemia, version 1.2015.
|
J Natl Compr Canc Netw
|
2014
|
1.02
|
|
37
|
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
|
Clin Cancer Res
|
2009
|
0.98
|
|
38
|
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
|
Int J Oncol
|
2002
|
0.93
|
|
39
|
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Haematologica
|
2011
|
0.90
|
|
40
|
Implementation of management guidelines for chronic myeloid leukemia: perspectives in the United States.
|
P T
|
2012
|
0.88
|
|
41
|
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2011
|
0.88
|
|
42
|
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.
|
Leuk Res
|
2012
|
0.88
|
|
43
|
Hodgkin lymphoma.
|
J Natl Compr Canc Netw
|
2011
|
0.88
|
|
44
|
Acute myeloid leukemia clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.87
|
|
45
|
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
|
Cancer Invest
|
2013
|
0.85
|
|
46
|
Chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2012
|
0.84
|
|
47
|
Hodgkin lymphoma, version 2.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.82
|
|
48
|
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.
|
Blood
|
2004
|
0.82
|
|
49
|
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
|
Leuk Lymphoma
|
2002
|
0.82
|
|
50
|
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.
|
Clin Cancer Res
|
2003
|
0.81
|
|
51
|
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
|
J Clin Oncol
|
2002
|
0.81
|
|
52
|
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
|
Cancer
|
2004
|
0.81
|
|
53
|
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.79
|
|
54
|
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.
|
Leuk Lymphoma
|
2013
|
0.79
|
|
55
|
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
|
J Clin Oncol
|
2002
|
0.79
|
|
56
|
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
|
Cancer
|
2009
|
0.79
|
|
57
|
Giant thoracic liposarcoma treated with induction chemotherapy followed by surgical resection.
|
J Thorac Oncol
|
2009
|
0.79
|
|
58
|
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.78
|
|
59
|
Chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2007
|
0.78
|
|
60
|
Acute myeloid leukemia.
|
J Natl Compr Canc Netw
|
2008
|
0.77
|
|
61
|
Chronic lymphocytic leukemia cell CD38 expression and inducible nitric oxide synthase expression are associated with serum IL-4 levels.
|
Leuk Res
|
2005
|
0.77
|
|
62
|
CLL cell apoptosis induced by nitric oxide synthase inhibitors: correlation with lipid solubility and NOS1 dissociation constant.
|
Leuk Res
|
2008
|
0.76
|
|
63
|
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
|
Biol Blood Marrow Transplant
|
2009
|
0.76
|
|
64
|
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.76
|
|
65
|
Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
66
|
Chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2005
|
0.75
|
|
67
|
High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series.
|
Am J Hematol
|
2003
|
0.75
|
|
68
|
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|
|
69
|
Hodgkin disease/lymphoma.
|
J Natl Compr Canc Netw
|
2008
|
0.75
|
|
70
|
Rituximab in lymphocyte predominance Hodgkin's disease: a case series.
|
Clin Lymphoma
|
2003
|
0.75
|
|
71
|
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.
|
Clin Lymphoma
|
2004
|
0.75
|
|
72
|
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2008
|
0.75
|
|
73
|
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
|
Cancer Invest
|
2010
|
0.75
|